Literature DB >> 33600462

Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".

Axel C Mühlbacher1,2, Andrew Sadler1.   

Abstract

Entities:  

Year:  2021        PMID： 33600462      PMCID： PMC7891755          DOI： 10.1371/journal.pone.0245480

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


× No keyword cloud information.
  8 in total

1.  Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA.

Authors:  Axel C Mühlbacher; Anika Kaczynski
Journal:  Appl Health Econ Health Policy       Date:  2016-02       Impact factor: 2.561

2.  The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.

Authors:  Axel C Mühlbacher; Andrew Sadler
Journal:  Value Health       Date:  2017-02-16       Impact factor: 5.725

3.  First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment.

Authors:  Axel Mühlbacher; Susanne Bethge
Journal:  Value Health       Date:  2016 Sep - Oct       Impact factor: 5.725

4.  Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Authors:  Axel C Mühlbacher; John F P Bridges; Susanne Bethge; Ch-Markos Dintsios; Anja Schwalm; Andreas Gerber-Grote; Matthias Nübling
Journal:  Eur J Health Econ       Date:  2016-02-04

5.  [The Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in Hepatitis C].

Authors:  Axel C Mühlbacher; Andrew Sadler
Journal:  Gesundheitswesen       Date:  2017-06-19

6.  Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations.

Authors:  Geert W J Frederix
Journal:  Pharmacoecon Open       Date:  2019-12

7.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  BMC Med       Date:  2013-03-25       Impact factor: 8.775

8.  Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.

Authors:  Afschin Gandjour
Journal:  PLoS One       Date:  2020-10-02       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.